Recurrent, IV-B Cervical cancer

Also known as: Cervical cancer stage IV / Metastatic Cervical Cancer / Stage IV Cervical Cancer / Carcinoma uterine cervix stage IV / Ca cervix stage IV / Cervix uteri cancer stage IV / Carcinoma uterine cerix stage IV / Cervical carcinoma stage IV / Cervix carcinoma stage IV / Carcinoma cervix stage IV

DrugDrug NameDrug Description
DB00112BevacizumabA recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.
DB00762IrinotecanIrinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
DB00642PemetrexedPemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.
DB01030TopotecanAn antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. [PubChem]
DB00361VinorelbineVinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) [L1998]. It was initially approved in the USA in 1990's for the treatment of NSCLC [L2010]. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting [A32347]. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug [L2002].
DrugDrug NameTargetType
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00112BevacizumabComplement C1r subcomponenttarget
DB00112BevacizumabComplement C1q subcomponent subunit Atarget
DB00112BevacizumabComplement C1q subcomponent subunit Btarget
DB00112BevacizumabComplement C1q subcomponent subunit Ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00112BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabVascular endothelial growth factor Atarget
DB00762IrinotecanDNA topoisomerase I, mitochondrialtarget
DB00762IrinotecanDNA topoisomerase 1target
DB00762IrinotecanCytochrome P450 3A4enzyme
DB00762IrinotecanCytochrome P450 3A5enzyme
DB00762IrinotecanUDP-glucuronosyltransferase 1-1enzyme
DB00762IrinotecanUDP-glucuronosyltransferase 1-9enzyme
DB00762IrinotecanLiver carboxylesterase 1enzyme
DB00762IrinotecanCytochrome P450 3A7enzyme
DB00762IrinotecanCytochrome P450 2B6enzyme
DB00762IrinotecanSolute carrier family 22 member 3transporter
DB00762IrinotecanSolute carrier organic anion transporter family member 1B1transporter
DB00762IrinotecanMultidrug resistance-associated protein 1transporter
DB00762IrinotecanATP-binding cassette sub-family G member 2transporter
DB00762IrinotecanSerum albumincarrier
DB00762IrinotecanCocaine esteraseenzyme
DB00762IrinotecanCholinesteraseenzyme
DB00762IrinotecanMultidrug resistance protein 1transporter
DB00762IrinotecanCanalicular multispecific organic anion transporter 1transporter
DB00642PemetrexedThymidylate synthasetarget
DB00642PemetrexedDihydrofolate reductasetarget
DB00642PemetrexedTrifunctional purine biosynthetic protein adenosine-3target
DB00642PemetrexedDeoxycytidine kinaseenzyme
DB00642PemetrexedBifunctional purine biosynthesis protein PURHtarget
DB00642PemetrexedEquilibrative nucleoside transporter 1enzyme
DB00642PemetrexedSolute carrier family 22 member 8transporter
DB01030TopotecanDNA topoisomerase I, mitochondrialtarget
DB01030TopotecanDNA topoisomerase 1target
DB01030TopotecanATP-binding cassette sub-family G member 2transporter
DB01030TopotecanMultidrug resistance protein 1transporter
DB01030TopotecanCytochrome P450 3A4enzyme
DB01030TopotecanDNAtarget
DB01030TopotecanMultidrug and toxin extrusion protein 1transporter
DB01030TopotecanMultidrug and toxin extrusion protein 2transporter
DB00361VinorelbineTubulin beta chaintarget
DB00361VinorelbineCytochrome P450 3A4enzyme
DB00361VinorelbineMultidrug resistance protein 1transporter
DB00361VinorelbineCytochrome P450 2D6enzyme
DrugDrug NamePhaseStatusCount
DB11714Durvalumab1Recruiting1
DB06215Ferumoxytol1Recruiting1
DB00762Irinotecan1Recruiting1
DB11771Tremelimumab1Recruiting1
DB07232Veliparib1Recruiting1
DB11595Atezolizumab2Active Not Recruiting1
DB00112Bevacizumab2Active Not Recruiting1
DB01259Lapatinib2Completed1
DB09035Nivolumab2Active Not Recruiting1
DB06589Pazopanib2Completed1
DB01275Hydralazine3Unknown Status1